Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

___
___
___
___

In this Spotlight On New Horizons in AL Amyloidosis, learn more about:

✓ The diagnosis of AL amyloidosis

✓ Treatment goals & current options available

✓ Clinical trial updates & new potential therapies

The impact of amyloid deposits in AL amyloidosis

Paolo Milani, MD, PhD
Amyloidosis Research & Treatment Center, Pavia, Italy

Bone marrow interstitial AL Amyloidosis and its microenvironment

Raymond Comenzo, MD
Tufts University School of Medicine, Boston, MA

Quantifying biomarkers to diagnose AL amyloidosis

Vaishali Sanchorawala, MD
Boston University School of Medicine, Boston, MA

Key highlights from ASH 2023: diagnosis & novel immunotherapeutic agents

Panel discussion with:

Vaishali Sanchorawala, MD
Boston University School of Medicine, Boston, MA

Ashutosh Wechalekar, MBBS
University College London, UK

Targeting the bone marrow microenvironment

Nikhil Munshi, MD
Dana-Farber Cancer Institute, Boston, MA

The current standard of care:
dara-CyBorD

Angela Dispenzieri, MD
Mayo Clinic, Rochester, MN

Unmet needs and limitations of the current SoC

Paolo Milani, MD, PhD
Amyloidosis Research & Treatment Center, Pavia, Italy

WEBINAR: Diagnosis, available therapies and the multidisciplinary approach

Panel discussion with:

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN

Ashutosh Wechalekar, MBBS, FRCP, FRCPath, DM, University College London, UK

Daniel Lenihan, MD, FACC, Saint Francis Healthcare System, Cape Girardeau, MO

Emerging therapies in AL amyloidosis
PRONTO & VITAL: pooled safety analysis of birtamimab

Vaishali Sanchorawala, MD
Boston University School of Medicine, Boston, MA

Treatment options available beyond
chemotherapy & transplant

Efstathios Kastritis, MD
University of Athens, Athens, Greece

The use of venetoclax in R/R AL amyloidosis

Eyal Lebel, MD
Hadassah Medical Center, Jerusalem, Israel

The role of the multidisciplinary team in treating patients with AL amyloidosis


The importance of the MDT to provide adequate treatment and care to patients

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy

More Videos
Investigating FLC secretion; a novel therapeutic approach

Giada Bianchi, MD
Dana-Farber Cancer Institute, Boston, MA

Accuracy of amyloidosis identification and referral to a specialty center

Vaishali Sanchorawala, MD
Boston University School of Medicine, Boston, MA

Dara-based regimens vs CyBorD & stage IIIb cardiac involvement

Paolo Milani, MD, PhD
Amyloidosis Research & Treatment Center, Pavia, Italy

Safety of HBI0101 (NXC-201):
a novel academic anti-BCMA CAR-T

Eyal Lebel, MD
Hadassah Medical Center, Jerusalem, Israel

Early diagnosis, treating relapsed disease & progression criteria

Angela Dispenzieri, MD
Mayo Clinic, Rochester, MN

Achieving complete hematologic response as a main goal of treatment

Vaishali Sanchorawala, MD
Boston University School of Medicine, Boston, MA

Immunotherapies & targeting amyloid plaque deposits

Angela Dispenzieri, MD
Mayo Clinic, Rochester, MN

This educational activity has received independent medical education support from Prothena.
This supporter has no influence over the production of the content.

 

The content of VJHemOnc is intended for healthcare professionals